IDEXX Laboratories, Inc.

Total Valuation

IDEXX Laboratories, Inc. carries a market capitalization of 42.23B, placing it among publicly traded companies globally. Its enterprise value stands at 42.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

IDEXX Laboratories, Inc. currently has 78.87M shares outstanding.

Valuation Ratios

IDEXX Laboratories, Inc. trades at a trailing price-to-earnings ratio of 36.79. The price-to-sales ratio is 9.21, and the price-to-book ratio stands at 25.75.

Enterprise Valuation

On an enterprise value basis, IDEXX Laboratories, Inc. trades at an EV/EBITDA multiple of 26.30 and an EV/FCF ratio of 27.62. The EV/Sales ratio of 9.32 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 29.08 provides insight into valuation relative to core operating earnings.

Financial Position

IDEXX Laboratories, Inc. maintains a current ratio of 1.17, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 67.97, indicating elevated leverage, while an interest coverage ratio of 42.68 demonstrates strong ability to service its debt obligations.

Financial Efficiency

IDEXX Laboratories, Inc. posts a return on equity of 74.21 and a return on invested capital of 42.80.

Taxes

Over the trailing twelve months, IDEXX Laboratories, Inc. has paid 284.76M in income taxes, reflecting an effective tax rate of 19.99.

Stock Price Statistics

IDEXX Laboratories, Inc.'s stock has declined approximately -16.40435% over the past 52 weeks. The 50-day moving average sits at 558.54, while the 200-day moving average is 607.81.

Income Statement

Over the trailing twelve months, IDEXX Laboratories, Inc. generated 4.55B in revenue and converted that into 1.14B in net income, yielding earnings per share of 14.22. EBITDA reached 1.61B, while operating income came in at 1.46B.

Balance Sheet

IDEXX Laboratories, Inc. holds 196.93M in cash and equivalents against 1.10B in total debt, resulting in a net debt position of 771.93M. Total book value stands at 1.61B, with working capital of 221.82M providing operational flexibility.

Cash Flow

IDEXX Laboratories, Inc. produced 1.37B in operating cash flow over the past twelve months. After subtracting -134.42M in capital expenditures, free cash flow totaled 1.24B - equivalent to 15.53 per share.

Margins

IDEXX Laboratories, Inc. operates with a gross margin of 62.45, reflecting its pricing power and cost economics. The operating margin of 32.03 and net profit margin of 25.03 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

IDEXX Laboratories, Inc.'s most recent stock split took place on June 16, 2015 with a 1:2 split ratio.

Scores

IDEXX Laboratories, Inc. posts an Altman Z-Score of 20.24, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.